55 results
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may also allow … basis for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
provides intensive guidance and organizational commitment involving senior managers in a proactive, collaborative, cross-disciplinary review, and may
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
for the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used … with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
10 Jul 23
Regulation FD Disclosure
4:06pm
, as potential in other potential in PWS, financing commitment hyperphagia, behaviors, well as protection of indications an orphan indication from Nantahala … Manufacturing Hub Services Patients Product Distribution 28 | © 2023 Soleno Therapeutics
FINANCIAL INFORMATION
Up to $60m financing commitment Leading
8-K
EX-99.1
6utgeg8s84otuhh0b 4q
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-1.1
99eqbfhp8qw in
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
424B5
p34jl7p5
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
yhdp2nx7d6yq6e22
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-99.1
385 qsvtl7uv
5 May 21
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:01pm
8-K
ozp1m7hy10hrh
15 Apr 21
Other Events
12:00am
8-K
EX-99.2
3kem c3u6t89s93
15 Apr 21
Other Events
12:00am
8-K
EX-1.1
je8 zq4zytrxi
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
mkmj rdmqp1dp55s0ff
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
mscg5rm0jm0
22 Oct 19
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
morgrwe g1oh3kmb4
29 Apr 19
Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors
4:03pm
424B3
5ar380c487vrp1y
12 Apr 19
Prospectus supplement
4:41pm
8-K
EX-10.1
93o1hcgeyj0d
19 Dec 18
Soleno Therapeutics Announces $16.5 Million Private Placement
4:02pm